Journal
FOODS
Volume 10, Issue 7, Pages -Publisher
MDPI
DOI: 10.3390/foods10071554
Keywords
metabolic syndrome; bioactive peptides; protein engineering; DPPIV; ACEI; antioxidant activity; lipid-lowering
Categories
Funding
- Secretaria de Investigacion y Posgrado - Consejo Nacional de Ciencia y Tecnologia (CONACyT)
Ask authors/readers for more resources
This study successfully designed a single protein with multiple bioactive peptides for the potential treatment of metabolic syndrome, providing in vitro evidence for its effectiveness and paving the way for the development of proteins to treat other non-communicable diseases.
Metabolic syndrome is a severe public health issue characterized by multiple metabolic disturbances. Current treatments prescribe a particular drug for each of them, producing multiple side effects. As a first step towards a more integral approach, we applied our recently described methodology to design single proteins, based in the Concanavalin B scaffold (1CNV), that contain several bioactive peptides (BPs), including antioxidant and lipid-lowering activities as well as inhibitors of dipeptidyl peptidase IV (DPPIV) and the angiotensin converting enzyme. Modified Concanavalin (CNV44), the designed protein that showed the best in silico properties, was expressed in high yields in E. coli and purified to homogeneity. After in vitro digestion with gastrointestinal enzymes, all the biological activities tested where higher in CNV44 when compared to the non-modified protein 1CNV, or to other previous reports. The results presented here represent the first in vitro evidence of a modified protein with the potential to treat metabolic syndrome and open the venue for the design of proteins to treat other non-communicable diseases.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available